At a Glance
Unichem Laboratories, the pharma underdog with a habit of making surprise comebacks, delivered a disappointing Q1 FY26. From ₹53 Cr profit last quarter to ₹10 Cr loss now, the script flipped hard. Revenue stayed decent at ₹527 Cr, but operational hiccups and rising costs dragged margins down. Stock tanked 7.4% to ₹563 – because investors hate plot twists that don’t end well.
Introduction
Remember Unichem’s story of phoenix-like rebirth with profit growth (29% CAGR in 5 years)? Well, Q1 FY26 just showed the bird face-planting mid-flight. The company operates in APIs, generics, and contract manufacturing, spanning cardio to neuro drugs. Yet, with volatile profits, low ROE (5.6%), and P/E at 29x, the market is asking – is this comeback over?
Business Model (WTF Do They Even Do?)
Unichem Laboratories thrives in three verticals:
- APIs: Active pharma ingredients sold globally.
- Formulations: Branded and non-branded generics across cardiology, gastro, psychiatry, neurology.
- CMO: Contract manufacturing for big pharma players.
They bet on a diversified therapy portfolio, but execution remains patchy.
Financials Overview
Q1 FY26 Snapshot:
- Revenue: ₹527 Cr (-10% QoQ)
- EBITDA: ₹22 Cr (Margin 4%) vs 14% last quarter
- Net Profit: ₹-10 Cr (loss)
- EPS: ₹-1.49
The pharma industry demands consistency, but Unichem’s numbers are more unpredictable than a Netflix thriller.
Valuation
